ContractPrincipia Biopharma Inc. • August 15th, 2018 • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LICENSE AGREEMENTLicense Agreement • August 15th, 2018 • Principia Biopharma Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of November 8, 2017 (the “Signing Date”) by and between, on the one hand, PRINCIPIA BIOPHARMA, INC., a Delaware corporation having its principal place of business at 400 East Jamie Court, Suite 302, South San Francisco, California 94080 (“Principia”), and, on the other hand, Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (“Sanofi”). Principia and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and PRINCIPIA BIOPHARMA INC. for RSK Inhibitors and Novel Electrophiles UC Case Nos. SF2003-057 & SF2009-119Exclusive License Agreement • August 15th, 2018 • Principia Biopharma Inc. • Pharmaceutical preparations • California
This amended and restated license agreement (“Agreement”) is made effective this 31st day of May, 2012 (“Amendment Effective Date”), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and acting through its Office of Technology Management, University of California San Francisco (“UCSF”), 185 Berry Street, Suite 4603, San Francisco, California 94107 and Principia Biopharma Inc., a Delaware corporation, having a principal place of business at 400 East Jamie Court, Suite 302, South San Francisco, California 94080 (“Licensee”).
PRINCIPIA BIOPHARMA INC. WARRANT TO PURCHASE STOCKPrincipia Biopharma Inc. • August 15th, 2018 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, [__], or such party’s assigns (the “Holder”), is entitled to subscribe for and purchase from PRINCIPIA BIOPHARMA INC., a Delaware corporation, with its principal office at 400 East Jamie Court, Suite 302, South San Francisco, CA 94080 (the “Company”) Warrant Shares at the Exercise Price (each subject to adjustment as provided herein).
